Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | VNN1 | O95497 | 13/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.37 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16685028 | 1.00 | PTGS1 (0.52) | PTGS1KCNH2VNN1ZDHHC20NAA50 | |
| SCHEMBL30456137 | 0.91 | PTGS1 (0.43) | PTGS1KCNH2VNN1ZDHHC20NAA50 | |
| SCHEMBL21996198 | 0.88 | PTGS1 (0.52) | PTGS1KCNH2VNN1ZDHHC20NAA50 | |
| SCHEMBL21996203 | 0.88 | PTGS1 (0.52) | PTGS1KCNH2VNN1ZDHHC20NAA50 | |
| Pantethine SCHEMBL9115760 | 0.88 | PTGS1 (0.54) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL1650348 | 0.87 | PTGS1 (0.56) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL19544641 | 0.87 | PTGS1 (0.56) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL59597 | 0.87 | PTGS1 (0.56) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| SCHEMBL21996375 | 0.87 | PTGS1 (0.48) | PTGS1KCNH2VNN1ZDHHC20NAA50 | |
| SCHEMBL21996378 | 0.87 | PTGS1 (0.48) | PTGS1KCNH2VNN1ZDHHC20NAA50 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107216-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2018022529-A1 | PANTETHEINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGIC DISORDERS | Retrophin, Inc. (US) | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107216-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | VNN1, NQO1, VKORC1 | PTGS1 1468/4885KCNH2 3526/4885VNN1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.